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challenged by payers and regulatory authorities to develop evidence describing 
the burden of illness and justifying the payer investment.  
 
HC2  
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Pan X1, Sambamoorthi U2 
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of 
Pharmacy, Morgantown, WV, USA  
OBJECTIVES: Determine the relationship between health care expenditures and 
depression in individuals with cancer compared to those with cancer and 
depression, after controlling for demographic, socio-economic, access to care 
and other health status variables. METHODS: Cross-sectional data on 4766 adults 
from multiple years (2006, 2007, 2008, and 2009) of the nationally representative 
household survey, Medical Expenditure Panel Survey (MEPS) were used. Cancer 
and depression was identified from Medical conditions file. Dependent variables 
consisted of total, inpatient, outpatient, emergency room, prescription drugs and 
other expenditures. OLS on logged dollars and generalized linear models with 
log-link were performed. All analyses accounted for the complex survey design 
of the MEPS. RESULTS: Overall, 14% of individuals with cancer reported having 
depression. Among individuals with cancer and depression the average health 
care expenditures were $18,401compared to $12,091 among those without 
depression. After adjusting for demographic, socio-economic, access to care and 
other health status variables, those with depression had about 32% greater total 
expenditures compared to those without depression. Expenditures for every type 
were higher among individuals with depression compared to those without 
depression. Individuals with cancer and depression were more significantly 
more likely to use emergency rooms (AOR = 1.46) and prescription drugs (AOR = 
3.56) compared to their counterparts without depression. CONCLUSIONS: Among 
adults with cancer, those with depression had higher health care utilization and 
expenditures compared to those without depression. Policy efforts to reduce 
excess health care expenditures associated with depression may include 
screening for depressive symptoms and preventing major depression, timely 
depression treatment once depression is detected.  
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OBJECTIVES: Following FDA approval, medical technology must still gain Centers 
for Medicare and Medicaid Services (CMS) coverage before Medicare 
reimbursement. However, the two agencies use approval processes based on 
different evidentiary standards. We identified the type and nature of 
discrepancies between FDA approval and CMS national coverage determinations 
(NCDs) for drugs and devices. METHODS: We used the Tufts Medical Center NCD 
database, which contains detailed information on 165 NCDs since 1999. For each 
device or Part B drug considered in an NCD (1999-2011) (n=69), we searched the 
FDA website to identify the approved indication. We classified CMS coverage as: 
more restrictive than FDA approval, i.e., conditions were placed on coverage 
beyond the FDA-approved label; equivalent to FDA approval; or less restrictive than 
FDA approval, i.e., CMS covers off-label indications. Further, we categorized 
conditions placed on CMS coverage as: “patient-related”, e.g., restricted to patients 
with certain comorbidities or characteristics; “place in therapy”, e.g., tied to use as 
second-line therapy; or “technology-related”, e.g., restricted to a particular 
application of the drug or device. RESULTS: CMS has covered FDA-approved 
drugs or devices taken through the Medicare NCD process in 80% of cases (55/69). 
For CMS covered drugs and devices (n=55), coverage was more restrictive in 32 
cases (58%), equivalent to FDA approval/clearance in 16 (29%), and less restrictive 
in seven (13%). Most common coverage restrictions were patient-related (78%), 
e.g., laparoscopic gastric banding to treat obesity is covered for patients suffering 
from an obesity-related comorbidity, and place in therapy (38%), e.g., coverage for 
extracorporeal immunoadsorption is covered for rheumatoid arthritis patients 
who have failed three disease-modifying antirheumatic drugs (DMARDs). In 
roughly one third of cases, CMS placed multiple restrictions on coverage. 
CONCLUSIONS: CMS coverage determinations are generally more restrictive 
than corresponding FDA approval. CMS often restricts coverage to patients with 
the most severe disease.  
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OBJECTIVES: To assess the patient-, hospital-, and discharge-level 
characteristics, and hospitalization rates among elderly patients with cancer in 
the United States (US). Hospitalization outcomes (length of stay [LOS], total 
charges, and mortality) among elderly patients with cancer were also studied. 
METHODS: A cross-sectional descriptive analysis of the 2009 Healthcare Cost 
and Utilization Project (HCUP) database was conducted. Patients were identified 
based on diagnosis (any-listed) of cancer using Clinical Classification Software 
(CCS). A control group of patients without cancer were identified by matching on 
age and gender (1:2 case-control). Analyses were conducted using PROC SURVEY 
procedures in SAS v9.2. RESULTS: In 2009, a total of 3,325,174 (weighted) 
hospitalizations occurred among elderly patients with cancer in the US. Elderly 
cancer patients had higher total hospital charges ($39,406 vs. $37,756), longer LOS 
(5.7 days vs. 5.4 days), and higher mortality (4.8% vs. 3.6%) as compared to those 
without cancer. A greater proportion of hospitalizations among cancer patients 
occurred in teaching hospitals (44.1% vs. 38.9%; p<0.001). In terms of location, a 
greater proportion of hospitalizations for cancer patients occurred in hospitals 
located in urban areas in comparison to those without cancer (88.1% vs. 84.7%; 
p<0.001). Total charges for hospitalizations among elderly patients with prostate 
(average LOS=4.9 days), lung (average LOS=6.1 days), and breast cancer (average 
LOS=4.9 days) were roughly $19.2, $16.1, and $16.0 billion, respectively. Mortality 
rates during hospitalization were the highest for those with pancreatic (10%), 
liver (9.7%), and lung cancer (8.7%). CONCLUSIONS: Elderly patients with cancer 
had significantly greater hospitalization burden as compared to those without 
cancer. Hospital mortality rates were the highest for elderly patients with 
pancreatic, liver, and lung cancer, respectively.  
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Inter-country variability in access to orphan drugs across countries has been 
highlighted in a number of studies. Understanding the reasons driving coverage 
decisions is a way forward in identifying areas where HTA methods may be 
improved. OBJECTIVES: Objectives are three-fold: a) to establish a 
methodological framework enabling to systematically compare HTA processes 
across countries; b) to identify the criteria driving HTA recommendations for a 
sample of orphan drugs, and; c) to understand the reasons for diverging 
recommendations and propose ways to minimize these. METHODS: All common 
orphan drug-indication pairs appraised in six countries (England, Scotland, 
France, Sweden, Canada and Australia) between 2001 and 2012 were selected. 
Agreement levels in HTA outcomes between countries were measured using 
Cohen’s kappa scores. Thematic analysis, by creating an NVivo-9 coding manual, 
was conducted to systematically compare each compound. Reasons for diverging 
HTA outcomes were differentiated based on whether they are a consequence of 
country-specific considerations or of the HTA process, and ranked by frequency 
of occurrences. RESULTS: Fourteen orphan drug-indication pairs were retrieved. 
Agreement in HTA outcomes was poor (k = [-0.5; 0.3]). Eight drug-indication pairs 
appraised by at least four HTA bodies were analyzed, five of which received 
diverging outcomes. Preliminary results suggest that in four of five cases, 
reasons for diverging recommendations were a consequence of the HTA process. 
Examples of non-homogeneous assessments include: lack of appropriate 
primary endpoint, lack of long-term data, evidence not reflecting clinical 
practice, orphan status or unmet clinical need. CONCLUSIONS: Preliminary 
results identify the criteria driving the assessments and reasons why they result 
in diverging HTA outcomes, enabling a better understanding of these processes 
by elucidating the expectations and value judgments from HTA bodies, 
particularly on the orphan status, and identifying areas where more consensus 
on what constitutes appropriate HTA methodologies is needed. Final results will 
quantify these criteria in a systematic manner.  
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OBJECTIVES: HTA agencies often review the same drugs for the same/similar 
indications. How often do agencies agree on their reimbursement decisions? 
Previous research has compared reimbursement recommendations (for the same 
drugs) for a limited number of agencies, but studies have rarely focused on more 
than 2 agencies. We collect and analyze a large number of health technology 
assessments from several countries to explore how often the agencies agree on 
their reimbursement decisions. METHODS: The data covered five agencies that 
make reimbursement decisions: NICE, SMC, PBAC, HAS and CADTH’s Common 
Drug Review. Our analysis only included decisions for drugs that were reviewed 
by at least two agencies. If a drug was reviewed multiple times by an agency for 
the same indication (i.e. resubmissions or updates) we used the most recent 
review for the analysis. A total of 78 drugs were reviewed by at least 2 agencies, 
producing a total of 195 reviews. RESULTS: There was generally a high level of 
agreement between all pairs of agencies, ranging from 56% (PBAC; CADTH) to 
91% (NICE; HAS). It is important to note that within the sample of drugs 
reviewed, all agencies issued positive recommendations at very high rates – all 
but CADTH issued positive recommendations for more than 80% of the drugs 
reviewed. This fact alone would produce high levels of agreement, even if 
agencies’ recommendations were statistically independent. Actual agreement 
rates observed were close to those implied by independence. CONCLUSIONS: 
Agencies agree on their reimbursement decisions quite often, but at rates close 
to those implied by their high overall positive recommendation rates alone. 
Future research will focus on identifying the determinants of agencies’ high 
rates of agreement.  
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OBJECTIVES: In developing new medicines, pharmaceutical companies face the 
complex and challenging task of choosing comparators, in the absence of clear 
and consistent guidance, in order to produce evidence that best meets diverse 
stakeholder needs. This lack of clear and consistent guidance has led to several 
high-profile cases in which HTA bodies rejected products receiving regulatory 
approval due to a lack of evidence relative to desired comparators. Our objective 
was to identify key issues in comparator selection and present case studies 
highlighting these issues. METHODS: We conducted a comprehensive search of 
the published and grey literature addressing comparator selection, including 
formal guidelines from major regulatory, HTA, and professional organizations, as 
well as case studies and published opinions. Three authors independently and 
qualitatively assessed the identified literature, and the final list of issues was 
agreed upon through team discussion and consensus. RESULTS: Key challenges 
in the selection of appropriate comparators include: 1) lack of a standard 
definition for “standard of care,” 2) concerns regarding off-label usage; 3) 
changes in requirements due to market dynamics; and 4) RCT design issues. We 
explore several of these challenges further with case studies. CONCLUSIONS: 
Due to challenges inherent in meeting diverse stakeholder needs, the selection 
of comparators is a complex and multi-faceted problem. The challenges we 
identified highlight the need for more uniformity and clarity among existing 
standards. In the context of ongoing external standard setting and 
harmonization efforts, organizations seeking to provide guidance around 
comparator selection should consider the issues described herein and work 
towards the common goal of a more transparent, harmonized process that 
optimizes the production of evidence that best meets the needs of all 
stakeholders.  
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OBJECTIVES: Gain insight into how HTA agencies evaluate biosimilar products 
and understand implications for future biosimilars. METHODS: Step I: Manually 
search 60 health care agencies’ websites for reports evaluating biosimilars. Step 
II: Categorize reports by HTA type, scope and outcome. Step III: Using a 
standardized set of categorical criteria, investigate HTA agencies’ approaches to 
biosimilar treatment recommendations, across multiple therapeutic areas. 
RESULTS: We identified a total of 47 HTA reports evaluating biosimilars, of 
which 38 are Single Technology Assessments (STA) and 9 are class reviews or 
clinical guidelines. Except for one STA by AMWSG, all recommendations were 
positive and no agency recognized substantial differences in clinical efficacy or 
safety between original and biosimilar products. A major factor influencing the 
negative AMWSG recommendation was limitations in the economic model 
provided by the sponsor company. After reviewing HTA reports on biosimilars, it 
is apparent that different countries apply different strategies to evaluating 
biosimilars – In France (13 STAs), Scotland (7 STAs) and Sweden (6 STAs), each 
biosimilar was reviewed individually; in Netherlands, CVZ published a 
“Preference policy for biologics” classifying biological products as “similar” and 
therefore therapeutically interchangeable. KCE (Belgian HTA body) chose this 
same approach and is currently studying the advantages and barriers of using 
biosimilars in Belgium. CONCLUSIONS: HTA agencies that have reviewed each 
biosimilar product individually, assessing all the available data through the full 
HTA process, have acknowledged the comparable safety and efficacy of 
biosimilar products with the original molecule. However, some individual 
restrictions were made in terms of prescribing patterns or formulation type 
limitations. Although the standard HTA path for biosimilars is not fully defined, 
we can conclude from this evaluation that HTA agencies generally treat 
biosimilars as equivalent in safety and efficacy to originator products.  
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OBJECTIVES: The Morisky Medication Adherence Scale (MMAS) has been 
validated in patients with hypertension using classic test theory analyses. Item 
Response Theory (IRT) methods are an increasingly popular, sophisticated 
means of validation in health outcomes research. The current study examined 
psychometric properties of the eight-item MMAS (MMAS-8) among hypertensive 
patients, using IRT. METHODS: Data were used from the U.S. 2012 National 
Health and Wellness Survey (NHWS; N=71,141), a web-based survey of patients’ 
demographics, health care attitudes and health outcomes. Respondents 
reporting physician diagnosis of hypertension and currently taking a 
prescription medication for hypertension were included. Reliability and validity 
of the MMAS-8 were examined using both classic test theory (Cronbach’s alpha) 
and IRT (two-parameter graded response model) analyses. RESULTS: Among 
16,680 patients with hypertension, 54.21% were male, mean age was 60.88 (SD = 
12.74) and years since diagnosis were 13.40 (SD=10.82). Non-adherence behavior 
frequencies varied across items; “do you have difficulty remembering to take all 
your medicine?” (28.92% “yes”), “do you sometimes forget to take your 
medicine?” (21.97%), “do you feel hassled about sticking to your treatment plan?” 
(16.21%) and “cut back or stopped taking your medicine because you felt worse 
when you took it?” (4.76%). The MMAS-8 was adequately reliable (Cronbach’s 
a=0.71); however, improvement was seen with removal of the “did you take all 
your medicine yesterday?” item (a=0.73). The eight items varied in their 
discrimination (range: 0.53–3.09), and item location parameters reflected a large, 
high range of non-adherence (0.68–4.79), indicating that the item set 
discriminates best at higher levels of non-adherence. CONCLUSIONS: The 
MMAS-8 has adequate psychometric properties for evaluating non-adherence in 
patients with hypertension, with room for improvement by eliminating one item 
and adding items that discriminate at lower levels of non-adherence. IRT is a 
helpful means for evaluating the reliability and validity of the MMAS-8.  
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OBJECTIVES: The 25-item National Eye Institute Visual Function Questionnaire 
(NEI VFQ-25) is widely used to assess patient-reported visual functioning. 
Previously, the reliability and validity of the NEI VFQ-25 has been assessed in 
patients with neovascular age-related macular degeneration (AMD). Its 
measurement performance in other ocular indications, and in large pooled 
datasets, remains unclear. This study aimed to evaluate the psychometric 
properties of the NEI VFQ-25 in a large sample of patients across multiple retinal 
diseases. METHODS: Dataset included pooled baseline NEI VFQ-25 data from six 
clinical trials in diabetic macular edema (DME), macular edema from branch and 
central retinal vein occlusion (RVO), neovascular AMD, and myopic choroidal 
neovascularisation. Rasch analysis was conducted by assessing item fit validity, 
threshold targeting, item dependency, reliability and stability. RESULTS: 
Measurement performance was evaluated for 2487 person measurements (mean 
age: 64±9 (SD) years; gender: 53% male). Mixed psychometric properties of the 
NEI VFQ-25 were identified. Key strengths identified included a high Person 
Separation Index of 0.93 (suggesting good reliability), predominantly low residual 
correlations (suggesting minimal local dependency between items), and no 
statistically significant Differential Item Functioning (suggesting stability of 
scoring function across country, study and gender). Some potential psychometric 
limitations of the NEI VFQ-25 included disordered thresholds for 15 of the 25 
items, poor fit according to the Rasch model for several items, and mismatched 
distributions of person and item threshold locations. These limitations suggest 
sub-optimal item targeting, potential problems with conceptual clarity, lack of 
discrimination across some response options and a consistent ceiling effect 
across all indications. CONCLUSIONS: Rasch analysis of NEI VFQ-25 identified 
many positive characteristics of this widely used instrument. Several suboptimal 
characteristics, however, were also identified, suggesting that changes to the NEI 
VFQ-25 could be considered to improve its psychometric performance in clinical 
trials of retinal diseases.  
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OBJECTIVES: To develop a patient-reported outcome (PRO) measure to assess the 
key functional and lifestyle impacts of chronic low back pain (cLBP) through 
qualitative concept elicitation (CE) and cognitive interviews. METHODS: Adult 
patients (18-80 years) with clinical diagnoses of cLBP of non-malignant origin 
experiencing moderate to severe levels of pain intensity were recruited in the 
U.S., UK, and Germany. Trained interviewers conducted CE and cognitive 
interview sessions with participating patients using semi-structured interview 
guides. The CE interviews elicited spontaneous reports of symptoms and 
associated impacts, followed by further probed exploration to confirm concepts. 
Cognitive interviews evaluated the degree of patient comprehension of the items 
in the draft PRO measure. All interview sessions were audio recorded and 
transcribed. The CE interviews were coded for qualitative content analysis using 
Atlas.ti, and cognitive interview transcripts were summarized in cognitive report 
tables. RESULTS: Forty-three CE interviews were conducted (mean age: 48.6±13.0, 
53.5% female, 74.4% -White/Caucasian). Mean pain NRS score was 6.7±1.3. A total 
of 2,220 impact expressions were derived from the transcripts, representing 47 
different impact concepts. Data from CE interviews was considered alongside 
existing measures, published literature and expert opinion to develop a 15-item 
draft instrument. Thirty additional patients participated in four waves of 
cognitive interviews, during which two items were removed and others were 
substantially modified to create the Pain Assessment for Low Back Impacts (PAL-
I). CONCLUSIONS: The PAL-I is a 13-item PRO measure for assessing lifestyle and 
functional impacts of cLBP that has been developed through direct qualitative 
patient involvement in accordance with the FDA’s PRO Guidance and scientific 
best practices. Cognitive interviews have provided evidence from patients that 
the measure is comprehensive, relevant to their cLBP experience, 
comprehendible, and easy to complete. The measure will be further tested in 
additional qualitative and quantitative studies to evaluate its measurement 
properties.  
